Febit Sets Roadmap for HybSelect Upgrades to Exploit 'Wide Open' Target-Enrichment Market

The Heidelberg, Germany-based firm is also developing with partners a whole-exome biochip that will contain "biomedically relevant" protein-encoding exons. The chip will be geared towards oncology researchers, but will also contain content for those studying neurological disorders and other diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.